Piper Sandler raised the firm’s price target on CytomX Therapeutics (CTMX) to $6.50 from $5 and keeps an Overweight rating on the shares. At SITC, CytomX presented Phase I data on Probody masked IFNalpha2b CX-801 in melanoma and preclinical data on Probody CDH3 T-cell engager CX-908. CytomX will present Phase I CX-801 data in combination with KEYTRUDA in advanced melanoma patients next year. Initial Phase I data on Probody masked EpCAM ADC CX-2051 showed doses of 7.2-10mg/kg achieved an impressive 28% ORR, 94% DCR and preliminary mPFS of 5.8 months in 3rd-line+ metastatic colorectal cancer.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Earnings Call Highlights Clinical Progress
- CytomX Therapeutics Reports Q3 2025 Financial Results
- CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
- CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
- Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051